In 2004 the national cancer research network, established in 2001, will be evaluated on a performance target of increasing recruitment of patients into cancer clinical trials. The national average in 2000-1 was 3.5% of incident cancer cases and the target was set at 7.5%. Much may depend on this target being met as £11.5m of government funding is being invested annually to provide infrastrucuture to conduct clinical trials within 34 networks across England. The future of this funding is not secure. We audited patients' involvement in clinical trials from a cohort of new cancer cases managed within a single research network to identify obstacles to recruitment.
Participants, methods, and results
The West Anglia cancer research network, a first wave regional research network, was established in 2001. It functions in close collaboration with the service based network. It covers a population of 1.65 million, and about 8000 new cases are seen each year. Patients discussed at weekly multidisciplinary team meetings are reviewed for their potential entry into trials. A database is kept of all patients considered for any clinical trial.
The figure summarises patients' data collected from team meetings in the cancer centre and four of the seven network cancer units during 2002. Of 1411 patients reviewed, 267 (19%) eventually entered a trial (the overall recruitment rate for our network in 2002 was actually 10%). No trial was available for 561 (40%) patients, and 390 (28%) were immediately excluded as they failed entry criteria. Of the 460 patients considered potentially eligible for trial entry, only 19 (4%) were not approached at all, 88 (19%) declined to take part, and 59 (13%) of those prepared to consider doing so ultimately failed screening procedures for specific trials. Overall, entry criteria disqualified 449 (53%) of the 850 patients for whom a trial was available.
Comment
The main reasons for cancer patients not entering a trial were lack of an available study and failure to meet entry criteria. is over £250m annually, of which 22% goes on research into treatment 1 and much of this is disproportionately channelled into "high profile" cancers such as breast, prostate, and leukaemia.
2 Rare cancers with poor prognosis are frequently overlooked.
We found that even when a trial was available eligibility criteria excluded over half of patients. It is a common criticism that the outcomes of trials for new treatments are superior to those subsequently encountered in standard clinical practice. Trials with broad entry criteria that better reflect everyday life will help with recruitment of patients 3 and probably yield more meaningful results.
Several national trials were not open for accrual in our research network because of lack of available service support and treatment costs. Although trusts are duty bound to provide support, our local research and development budgets are insufficient to meet the needs, while commissioners are in no financial position to be prioritising research over service needs. The onus must be on funding bodies and principal investigators of new trials to ensure adequate resourcing from the outset.
Finally, of those patients who were approached to enter a trial, one in five declined. Little is known about the factors that influence men and women to take part in clinical trials. 4 There is much scope to involve consumers more actively in clinical research and encourage a partnership approach to improving cancer care.
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Effect of national guidelines on prescription of methadone: analysis of NHS prescription data, England 1990-2001
John Strang, Janie Sheridan
Though there is strong evidence to support the use of methadone maintenance for opiate addiction 1 it is often delivered poorly. Evidence based guidelines were developed in 1996 and 1999 (see www.doh.gov.uk/ drugdep.htm and further details on bmj.com) and widely publicised in the United Kingdom.
2 3 In 1998 we found scant evidence of any impact 4 and concluded that "if planners are awaiting major change in methadone prescribing as a result of central exhortation, they should not hold their breath." However, perhaps guidelines may have a slower cumulative effect.
Method and results
We examined data on all NHS methadone prescriptions dispensed by community pharmacists in England. These account for 98% of methadone prescriptions in England.
5
Unpublished commercial data indicate that 95% of methadone prescriptions from general practitioners are for addiction treatment (IMS Health).
To investigate the impact of the guidelines we used two specific recommendations from the Department of Health (the 1996 taskforce report and the Orange Guidelines 1999): firstly, that prescribing of methadone in tablet form should cease (based on concerns about intravenous misuse), and, secondly, that injectable methadone (methadone ampoules) should not be prescribed as mainstream treatment. We examined the proportion of methadone prescriptions per year issued as oral syrup, tablets, or injectable ampoules to identify any change of professional practice.
We examined the six years preceding 1996 (1990-5) to establish prevailing trends in methadone prescribing and then the six years during which the new guidelines were introduced (1996) (1997) (1998) (1999) (2000) (2001) to study any change. Between 1990 and 2001, NHS prescriptions for methadone dispensed in England tripled-from 425 400 to 1 318 100 annually-increasing every year. However, the proportionate annual increase fell from 15.3%, 23.8%, and 21.1% (first three years) down to increases of 2.7%, 3.6%, and 3.8% (last three years) (table) .
Over the six year baseline period , the proportion of methadone prescriptions prescribed as tablets was steady at between 7.8% and 9.8% annually. Thereafter, the proportion steadily reduced (1% per annum) to 4.0% by 2001, and the absolute number also fell every year. Similarly, prescriptions for injectable methadone were stable for 1990-5 (range 8.0% to 9.7%, peaking at 9.7% in 1994) but steadily reduced thereafter, from 8.7% in 1995 to 3.9% in 2001. From 1997 the absolute number of prescriptions as ampoules fell annually.
Comment
Over the past decade, the extent of methadone prescribing in England has tripled, deriving from a See bmj.com for details of the national guidance
